HTHemeesh Tandel

Hemeesh Tandel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hemeesh Tandel has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis

    by Anika Goel, Muhammad Abdullah Naveed, Hemeesh Tandel, Affaf Mahmood, Muhammad Mukhlis, K. Sai Varun Reddy, Arun Kumar Maloth, Anchit Chauhan, Ameer Awashra, Amogh Verma, et al.

    Background: Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in secondary prevention is needed. Methods: We conducted a systematic review and meta‐analysis of randomised controlled trials evaluating evolocumab in adults with established cardiovascular disease. PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched through April 2025. Outcomes included lipid parameters, major adverse cardiovascular events (MACE), individual cardiovascular endpoints, and safety, with pooled risk ratios (RR) and mean differences calculated using random‐effects models. Results: Nine trials enrolling 67,662 patients were included. Evolocumab significantly reduced LDL‐C (mean difference −57.73 mg/dL), total cholesterol (−52.27 mg/dL), triglycerides (−21.21 mg/dL), and lipoprotein(a) (−10.99 mg/dL), while increasing HDL‐cholesterol (3.69 mg/dL). Evolocumab was associated with lower MACE (RR 0.53; 95% CI 0.40–0.71), though this estimate should be interpreted cautiously given heterogeneity in endpoint definitions and study designs. Myocardial infarction (RR 0.74) and coronary revascularisation (RR 0.80) were significantly reduced, while cardiovascular mortality and stroke showed no statistically definitive reduction. Serious adverse events and neurocognitive effects were comparable between groups, though injection‐site reactions were more frequent with evolocumab. Conclusion: In patients with established cardiovascular disease, evolocumab provides substantial lipid lowering and reduces ischemic events without major safety concerns, supporting its use as an adjunct to statin therapy in secondary prevention.

  • Open Access

    Using Hepatitis B Surface Antigen–Positive Donors in Liver Transplantation: Outcomes, Prophylaxis, and Monitoring with a Focus on Hepatitis B Virus–Naive Recipients

    by Ali Emre Bardak, Aafeen Mujeeb, Ayse Eylul Donmez, Nazli Begum Ozturk, Eda Yildiz, Hemeesh Tandel, Merih Deniz Toruner, Merve Gurakar, Behnam Saberi, Nilay Danis, et al.

    Liver transplantation (LT) remains the only definitive treatment for end-stage liver disease and selected hepatic malignancies. However, persistent organ shortages continue to drive high waitlist mortality worldwide. Hepatitis B virus (HBV)-positive donors, including hepatitis B surface antigen (HBsAg)-positive and anti-hepatitis B core antibody–positive (HBsAg negative) donors, represent an increasingly important but historically underused resource. The introduction of high-barrier nucleos(t)ide analogs, the selective use of hepatitis B immunoglobulin, and pre- and posttransplant vaccination have markedly reduced viral transmission, enabling safe transplantation in both HBV-immune and selected HBV-naive recipients. Regional guidelines and consensus statements, including those from the American Society of Transplantation, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, and Asian Pacific Association for the Study of the Liver, support individualized, risk-directed prophylaxis and posttransplant surveillance. Ethical considerations, particularly informed consent and risk–benefit discussions in the setting of organ scarcity, remain central to clinical decision-making. Large cohort studies demonstrate comparable graft and patient survival with HBV-negative grafts, along with economic advantages and expansion of the donor pool. However, evidence in HBV-naive recipients remains limited, with most data derived from immune or previously infected recipients, highlighting the need for careful patient selection and robust prophylaxis. Available evidence on the use of HBsAg-positive donors in HBV-naive recipients is obtained predominantly from cadaveric donor transplantation, as experience with HBsAg-positive living donors remains limited. This narrative review summarizes current evidence on the use of HBsAg-positive grafts in LT, with a focus on HBV-naive recipients, based predominantly on cadaveric donor experience. Cite this article as: Bardak AE, Mujeeb A, Donmez AE, et al. Using hepatitis B surface antigen–positive donors in liver transplantation: Outcomes, prophylaxis, and monitoring with a focus on hepatitis B virus–naive recipients. Turk J Gastroenterol. Published online May 13, 2026. doi: 10.5152/tjg.2026.26018.

  • Emotional Turmoil: A Case of Takotsubo Cardiomyopathy in a Young Adult

    by Aelaf Mammo, Amirhossein Farahani, Yasin Sabzevaran, Sachi Chavda, Mirab Singh, Hemeesh Tandel, Zhang Ming

    Takotsubo cardiomyopathy (TTC), or "broken heart syndrome," is a transient cardiac condition marked by left ventricular dysfunction, often triggered by emotional or physical stress. This case report discusses a 28-year-old female who developed TTC after the sudden loss of a close family member. She presented to the emergency department with acute chest pain, dyspnea, and anxiety, resembling acute myocardial infarction. ECG showed ST-segment elevations and T-wave inversions, while lab tests revealed elevated cardiac biomarkers, including troponin. An echocardiogram confirmed classic apical ballooning, and coronary angiography ruled out obstructive coronary artery disease, showing normal arteries. The patient received supportive care, including beta-blockers and anxiolytics, and her symptoms improved, with follow-up echocardiography showing normal left ventricular function within weeks. This case highlights the need for awareness of TTC in younger patients under emotional stress and the importance of timely diagnosis and management to avoid unnecessary interventions.